Expert Opinion on Therapeutic Targets最新文献_第4页

Expression of Concern: Overexpression of HMGA2 in breast cancer promotes cell proliferation, migration, invasion and stemness. 关注表达：乳腺癌中 HMGA2 的过表达会促进细胞增殖、迁移、侵袭和干性。

IF 5.4 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-10-01 Epub Date: 2024-10-21 DOI: 10.1080/14728222.2024.2417515

引用次数: 0

The role of Nrf2 in immune cells and inflammatory autoimmune diseases: a comprehensive review. Nrf2 在免疫细胞和炎症性自身免疫疾病中的作用：全面综述。

IF 5.8 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-09-10 DOI: 10.1080/14728222.2024.2401518

Wang-Dong Xu,Chan Yang,An-Fang Huang

{"title":"The role of Nrf2 in immune cells and inflammatory autoimmune diseases: a comprehensive review.","authors":"Wang-Dong Xu,Chan Yang,An-Fang Huang","doi":"10.1080/14728222.2024.2401518","DOIUrl":"https://doi.org/10.1080/14728222.2024.2401518","url":null,"abstract":"INTRODUCTIONNrf2 regulates mild stress, chronic inflammation, and metabolic changes by regulating different immune cells via downstream signaling. Collection of information about the role of Nrf2 in inflammatory autoimmune diseases will better understand the therapeutic potential of targeting Nrf2 in these diseases.AREAS COVEREDIn this review, we comprehensively discussed biological function of Nrf2 in different immune cells, including Nrf2 preventing oxidative tissue injury, affecting apoptosis of immune cells and inflammatory cytokine production. Moreover, we discussed the role of Nrf2 in the development of inflammatory autoimmune diseases.EXPERT OPINIONNrf2 binds to downstream signaling molecules and then provides durable protection against different cellular and organ stress. It has emerged as an important target for inflammatory autoimmune diseases. Development of Nrf2 modulator drugs needs to consider factors such as target specificity, short/long term safety, disease indication identification, and the extent of variation in Nrf2 activity. We carefully discussed the dual role of Nrf2 in some diseases, which helps to better target Nrf2 in the future.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":"12 1","pages":"1-18"},"PeriodicalIF":5.8,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142178925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Can we target insulin signalling for cognition therapeutics? 我们能否针对胰岛素信号进行认知治疗？

IF 4.6 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-09-01 Epub Date: 2024-09-24 DOI: 10.1080/14728222.2024.2407821

Simone Macrì, Giovanni Laviola

引用次数: 0

Combined cancer immunotherapy based on targeting adenosine pathway and PD-1/PDL-1 axis. 以腺苷通路和 PD-1/PDL-1 轴为靶点的联合癌症免疫疗法。

IF 4.6 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-09-01 Epub Date: 2024-09-20 DOI: 10.1080/14728222.2024.2405090

Mehrdad Fathi, Asieh Zarei, Ata Moghimi, Pooya Jalali, Zahra Salehi, Sharareh Gholamin, Farhad Jadidi-Niaragh

{"title":"Combined cancer immunotherapy based on targeting adenosine pathway and PD-1/PDL-1 axis.","authors":"Mehrdad Fathi, Asieh Zarei, Ata Moghimi, Pooya Jalali, Zahra Salehi, Sharareh Gholamin, Farhad Jadidi-Niaragh","doi":"10.1080/14728222.2024.2405090","DOIUrl":"10.1080/14728222.2024.2405090","url":null,"abstract":"Introduction: Cancer immunotherapy has revolutionized the field of oncology, offering new hope to patients with advanced malignancies. Tumor-induced immunosuppression limits the effectiveness of current immunotherapeutic strategies, such as PD-1/PDL-1 checkpoint inhibitors. Adenosine, a purine nucleoside molecule, is crucial to this immunosuppression because it stops T cells from activating and helps regulatory T cells grow. Targeting the adenosine pathway and blocking PD-1/PDL-1 is a potential way to boost the immune system's response to tumors.Areas covered: This review discusses the current understanding of the adenosine pathway in tumor immunology and the preclinical and clinical data supporting the combination of adenosine pathway inhibitors with PD-1/PDL-1 blockade. We also discuss the challenges and future directions for developing combination immunotherapy targeting the adenosine pathway and the PD-1/PDL-1 axis for cancer treatment.Expert opinion: The fact that the adenosine signaling pathway controls many immune system processes suggests that it has a wide range of therapeutic uses. Within the next five years, there will be tremendous progress in this area, and the standard of care for treating malignant tumors will have switched from point-to-point therapy to the integration of immunological networks comprised of multiple signaling pathways, like the adenosine axis.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"757-777"},"PeriodicalIF":4.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapeutic indications for HDAC6 inhibitors in the peripheral and central nervous disorders. HDAC6 抑制剂在外周和中枢神经疾病中的治疗适应症。

IF 4.6 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-09-01 Epub Date: 2024-09-20 DOI: 10.1080/14728222.2024.2404571

Jonathan van Eyll, Robert Prior, Sylvain Celanire, Ludo Van Den Bosch, Frederik Rombouts

{"title":"Therapeutic indications for HDAC6 inhibitors in the peripheral and central nervous disorders.","authors":"Jonathan van Eyll, Robert Prior, Sylvain Celanire, Ludo Van Den Bosch, Frederik Rombouts","doi":"10.1080/14728222.2024.2404571","DOIUrl":"10.1080/14728222.2024.2404571","url":null,"abstract":"Introduction: Inhibition of the enzymatic function of HDAC6 is currently being explored in clinical trials ranging from peripheral neuropathies to cancers. Advances in selective HDAC6 inhibitor discovery allowed studying highly efficacious brain penetrant and peripheral restrictive compounds for treating PNS and CNS indications.Areas covered: This review explores the multifactorial role of HDAC6 in cells, the common pathological hallmarks of PNS and CNS disorders, and how HDAC6 modulates these mechanisms. Pharmacological inhibition of HDAC6 and genetic knockout/knockdown studies as a therapeutic strategy in PNS and CNS indications were analyzed. Furthermore, we describe the recent developments in HDAC6 PET tracers and their utility in CNS indications. Finally, we explore the advancements and challenges with HDAC6 inhibitor compounds, such as hydroxamic acid, fluoromethyl oxadiazoles, HDAC6 degraders, and thiol-based inhibitors.Expert opinion: Based on extensive preclinical evidence, pharmacological inhibition of HDAC6 is a promising approach for treating both PNS and CNS disorders, given its involvement in neurodegeneration and aging-related cellular processes. Despite the progress in the development of selective HDAC6 inhibitors, safety concerns remain regarding their chronic administration in PNS and CNS indications, and the development of novel compound classes and modalities inhibiting HDAC6 function offer a way to mitigate some of these safety concerns.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"719-737"},"PeriodicalIF":4.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Innovations in treating acute graft-versus-host disease: a review of preclinical targets and strategies. 治疗急性移植物抗宿主疾病的创新：临床前靶点和策略综述。

IF 4.6 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-09-01 Epub Date: 2024-09-19 DOI: 10.1080/14728222.2024.2405091

Haoliang Duan, Yuhua Ru, Jia Chen

{"title":"Innovations in treating acute graft-versus-host disease: a review of preclinical targets and strategies.","authors":"Haoliang Duan, Yuhua Ru, Jia Chen","doi":"10.1080/14728222.2024.2405091","DOIUrl":"10.1080/14728222.2024.2405091","url":null,"abstract":"Introduction: Acute graft-versus-host disease (aGVHD) is a major complication of post-allogeneic hematopoietic stem cell transplantation (allo-HSCT) that severely impacts patient survival and quality of life. Despite advancements in standard care, therapeutic outcomes remain suboptimal, necessitating the exploration of innovative strategies.Areas covered: This review synthesizes preclinical research focusing on novel therapeutic targets and strategies that may enhance treatment efficacy. We critically analyzed the role of specific T-cell subsets, cytokine modulators, and intracellular signaling pathways in reducing aGVHD severity. Emphasis is placed on experimental findings that illuminate the mechanisms of immune tolerance and survival improvement. We discuss the translation of these findings into potential clinical trials and evaluate the challenges and progress in implementing these strategies, including scalability and impact on the graft-versus-leukemia (GVL) effect.Expert opinion: Our review summarizes the latest therapeutic targets and strategies in preclinical research for aGVHD, aiming to bridge the gap between clinical and experimental medicine. By integrating immunology, genetics, and cytology, we seek to enhance the translation of preclinical findings into clinical strategies. This multidisciplinary approach is expected to improve patient outcomes in aGVHD treatment, ultimately leading to more effective and safer therapies.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"807-824"},"PeriodicalIF":4.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The endocannabinoid system as a therapeutic target in neuropathic pain: a review. 内源性大麻素系统作为神经性疼痛的治疗靶点：综述。

IF 4.6 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-09-01 Epub Date: 2024-09-24 DOI: 10.1080/14728222.2024.2407824

Jose-Manuel Quintero, Luis-Eduardo Diaz, Ismael Galve-Roperh, Rosa-Helena Bustos, Marta-Ximena Leon, Stephania Beltran, Seetal Dodd

{"title":"The endocannabinoid system as a therapeutic target in neuropathic pain: a review.","authors":"Jose-Manuel Quintero, Luis-Eduardo Diaz, Ismael Galve-Roperh, Rosa-Helena Bustos, Marta-Ximena Leon, Stephania Beltran, Seetal Dodd","doi":"10.1080/14728222.2024.2407824","DOIUrl":"https://doi.org/10.1080/14728222.2024.2407824","url":null,"abstract":"Introduction: This review highlights the critical role of the endocannabinoid system (ECS) in regulating neuropathic pain and explores the therapeutic potential of cannabinoids. Understanding the mechanisms of the ECS, including its receptors, endogenous ligands, and enzymatic routes, can lead to innovative treatments for chronic pain, offering more effective therapies for neuropathic conditions. This review bridges the gap between preclinical studies and clinical applications by emphasizing ECS modulation for better pain management outcomes.Areas covered: A review mapped the existing literature on neuropathic pain and the effects of modulating the ECS using natural and synthetic cannabinoids. This analysis examined ECS components and their alterations in neuropathic pain, highlighting the peripheral, spinal, and supraspinal mechanisms. This review aimed to provide a thorough understanding of the therapeutic potential of cannabinoids in the management of neuropathic pain.Expert opinion: Advances in cannabinoid research have shown significant potential for the management of chronic neuropathic pain. The study emphasizes the need for high-quality clinical trials and collaborative efforts among researchers, clinicians, and regulatory bodies to ensure safe and effective integration of cannabinoids into pain management protocols. Understanding the mechanisms and optimizing cannabinoid formulations and delivery methods are crucial for enhancing therapeutic outcomes.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":"28 9","pages":"739-755"},"PeriodicalIF":4.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Looking ahead to targeting macrophages by CAR T- or NK-cells in blood cancers. 展望在血癌中使用 CAR T 细胞或 NK 细胞靶向巨噬细胞。

IF 4.6 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-09-01 Epub Date: 2024-09-05 DOI: 10.1080/14728222.2024.2400075

David Kegyes, Paul Alexandru Milea, Andreea-Isabella Mazga, Adrian-Bogdan Tigu, Madalina Nistor, Diana Cenariu, Radu Tomai, Sanda Buruiana, Hermann Einsele, Alina Daniela Tănase, Ciprian Tomuleasa

{"title":"Looking ahead to targeting macrophages by CAR T- or NK-cells in blood cancers.","authors":"David Kegyes, Paul Alexandru Milea, Andreea-Isabella Mazga, Adrian-Bogdan Tigu, Madalina Nistor, Diana Cenariu, Radu Tomai, Sanda Buruiana, Hermann Einsele, Alina Daniela Tănase, Ciprian Tomuleasa","doi":"10.1080/14728222.2024.2400075","DOIUrl":"10.1080/14728222.2024.2400075","url":null,"abstract":"Introduction: The bone marrow microenvironment (BME) is critical for healthy hematopoiesis and is often disrupted in hematologic malignancies. Tumor-associated macrophages (TAMs) are a major cell type in the tumor microenvironment (TME) and play a significant role in tumor growth and progression. Targeting TAMs and modulating their polarization is a promising strategy for cancer therapy.Areas covered: In this review, we discuss the importance of TME and different multiple possible targets to modulate immunosuppressive TAMs such as: CD123, Sphingosine 1-Phosphate Receptors, CD19/CD1d, CCR4/CCL22, CSF1R (CD115), CD24, CD40, B7 family proteins, MARCO, CD47, CD163, CD204, CD206 and folate receptors.Expert opinion: Innovative approaches to combat the immunosuppressive milieu of the tumor microenvironment in hematologic malignancies are of high clinical significance and may lead to increased survival, improved quality of life, and decreased toxicity of cancer therapies. Standard procedures will likely involve a combination of CAR T/NK-cell therapies with other treatments, leading to more comprehensive cancer care.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"779-787"},"PeriodicalIF":4.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An overview of Skp2: a promising new therapeutic target of psoriasis. Skp2概述：银屑病有望成为新的治疗靶点。

IF 4.6 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-08-01 Epub Date: 2024-08-05 DOI: 10.1080/14728222.2024.2387604

Yashika Tomar, Moushumi Baidya, Jay Chadokiya, Shvetank Bhatt, Gautam Singhvi

{"title":"An overview of Skp2: a promising new therapeutic target of psoriasis.","authors":"Yashika Tomar, Moushumi Baidya, Jay Chadokiya, Shvetank Bhatt, Gautam Singhvi","doi":"10.1080/14728222.2024.2387604","DOIUrl":"10.1080/14728222.2024.2387604","url":null,"abstract":"Introduction: Psoriasis is a chronic immune-mediated disorder affecting over 2-3% of the population worldwide, significantly impacting quality of life. Despite the availability of various therapeutic interventions, concerns persist regarding lesion recurrence and potential alterations in immune surveillance promoting cancer progression. Recent advancements in understanding cellular and molecular pathways have unveiled key factors in psoriasis etiology, including IL-17, 22, 23, TNF-α, PDE-4, JAK-STAT inhibitors, and AhR agonists. This work explores the potential of S-phase kinase-associated protein 2 (Skp2) as a therapeutic target in psoriasis.Area covered: This review covers the current understanding of psoriasis pathophysiology, including immune dysregulation, and the role of keratinocytes and ubiquitin. It also delves into Skp2 role in cell cycle regulation, and its correlation with angiogenesis and ubiquitin in psoriasis. The evolving therapeutic approaches targeting Skp2, including small molecule inhibitors, are also discussed.Expert opinion: Targeting Skp2 holds promise for developing novel therapeutic approaches for psoriasis. By modulating Skp2 activity or expression, it may be possible to intervene in inflammatory and proliferative processes underlying the disease. Further research into Skp2 inhibitors and their efficacy in preclinical and clinical settings is warranted to harness the full potential of Skp2 as a therapeutic target in psoriasis management.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"689-700"},"PeriodicalIF":4.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141859466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The emerging role of Tetraspanin 32 in autoimmune diseases: from discovery to relevant theranostics? 四泛素 32 在自身免疫性疾病中的新作用：从发现到相关治疗？

IF 4.6 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-08-01 Epub Date: 2024-08-13 DOI: 10.1080/14728222.2024.2389203

Paolo Fagone, Katia Mangano, Ferdinando Nicoletti

引用次数: 0